The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The VDR ligandbinding domain is a molecular switch, since its ligand-triggered interactions with corepressor and coactivator proteins are the central molecular events of nuclear 1α,25(OH)2D3 signaling. 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis. Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists. In this review we discuss the molecular mechanisms of these different type of analogues based on crystal structure data, molecular dynamics simulations and biochemical assays.
INTRODUCTION
Nuclear receptors (NRs) form the largest family of metazoan transcription factors and regulate the expression of target genes that affect processes as diverse as reproduction, development and metabolism [1] . Fat-soluble hormones and intermediary metabolites are particularly well suited to mediate intercellular communication because, unlike watersoluble peptide hormones, they can pass freely through the lipid bilayer of the cell membrane. Therefore, dietary lipids, such as cholesterol and fatty acids, and their metabolites, such as steroids and oxysterols, act as ligands to many of the 48 NRs encoded by the human genome [2] . Several NRs are pharmaceutical drug targets for the treatment of diverse diseases, such as asthma, type 2 diabetes, atherosclerosis, osteoporosis and cancer. To aid intervention in these diseases, multiple synthetic NR agonists, antagonists and inverse agonists have been synthesized and characterized [3] . Although, the physiology of NRs and their natural and synthetic ligands shows broad variety, their actions can be summarized to a couple of common gene regulatory mechanisms. These principles will be discussed first before addressing specifically the NR for 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), VDR.
NR SIGNALING
The basis of the common actions of NRs is hidden in their conserved molecular structure. Members of the NR superfamily are identified by the presence of a highly conserved DNA-binding domain (DBD) and a structurally conserved ligand-binding domain (LBD) [4] (Fig. 1) . The LBD of most NRs is a characteristic 3-layer anti-parallel α-*Address correspondence to this author at the Department of Biochemistry, University of Kuopio, P.O. box 1627, FIN-70211 Kuopio, Finland; Tel: +358-17-163062; Fax: +358-17-2811510; E-mail: carlberg@messi.uku.fi helical sandwich formed by 11-13 α-helices [5] (Fig. 2) . NR ligands share in common a mainly non-polar character, but they vary greatly in chemical structure. This is complemented by a similar diversity in the LBDs themselves. In the lower half of the LBD there is no central helical layer but a large non-polar pocket, to which the various lipophilic ligands bind [6] . The interior surface of these ligand-binding pockets is mostly made up from non-polar amino acids and thereby complements the character of the various ligands. Specificity is achieved through a limited number of stereospecific polar contacts, the so-called anchoring points (Fig.  3) , and the actual shape of the cavity. NRs that bind with high affinity to a specific ligand, such as the estrogen receptor (ER) [7] , have small ligand-binding pockets. Other members of the NR superfamily, the so-called adopted orphans, such as peroxisome proliferator-activated receptors (PPARs) [8] and the pregnane X receptor (PXR) [9] , are more promiscuous in the binding of numerous ligands with lower affinity and have much larger ligand-binding pockets that can accommodate various ligands in different orientations. The volume of these pockets ranges from 400 to more than 1400 Å 3 and the increased size is created by an opening up of the helical framework [6] . In addition, there are a number of orphan members of the NR superfamily that are not regulated by conventional ligand binding and either have constitutive activity, no ligand-binding pocket or their activity is regulated via post-translational modifications, such as phosphorylation and acetylation.
Comparison of the structure of the apo-retinoid X receptor (RXR) [10] with the ligand-bound retinoid acid receptor (RAR) [11] suggested that receptors undergo a specific switch between two conformations, which involves a major rearrangement of H12 as well as a number of more subtle changes. In the ligand-bound agonistic conformation, one side of the ligand-binding pocket is sealed by H12, which serves as a molecular switch by allowing the LBD in its agonistic conformation to interact with co-activator (CoA) proteins, such as SRC-1, TIF2 and RAC3 [12] (Fig. 1) . In the absence of an agonistic ligand, NRs interact with corepressor (CoR) proteins, such as NCoR, SMRT and Alien [13] . CoA and CoR proteins both contain multiple, short receptor interaction domains (RIDs), composed of the sequence LXXLL (L = leucine, X = any amino acid) in case of CoAs [14] and LXXXIXXX(I/L) in case of CoRs [15] . The RID containing peptides make contacts with helices 3, 4 and 12 of the NR LBD. This interaction is stabilized by an evolutionary conserved charge clamp that is formed between a glutamate in H12 and either a lysine in H3 (in the case of CoA binding) or a lysine in H4 (for contacting CoR). CoAs and CoRs interact with the same hydrophobic groove on the surface of the LBD [5] . This provides the advantage that binding of the two co-regulators is mutually exclusive and creates a bipolar "switch" of two extremes.
The choice of co-regulator is the molecular switch that is controlled by ligand binding. It is evident that a particular position of H12 is essential to support CoA binding. The "mouse-trap" model [16] proposes that H12 acts as a lid to the ligand-binding pocket of the LBD, which has to be closed in order to allow NR interaction with CoAs and open, when the receptor contacts CoRs. This implies that while H12 takes only one defined position in the agonist-bound receptor, multiple positions of the helix may be possible in antagonist-bound or apo-receptors. This view will be revised later in this review. The structures of the PPAR and PXR LBDs suggest that the mechanism of the molecular switch might be less drastic than deduced from the extreme case of apo-RXR [8, 9, 17] . At the example of the complex of PPARα with a CoR RID peptide it has been shown that a synthetic antagonist can prevent H12 from adopting the active conformation. This facilitates CoR binding and the respective ligand can be considered an inverse agonist [18] .
THE DYNAMICS OF NR LBDs
Crystallographic studies of NRs have been complemented by other biochemical methods, such as limited protease digestion assays, which use protein degrading enzymes to cleave differently exposed protein surfaces in a conformationdependent manner [19] . This assay demonstrates that apoLBDs are generally more sensitive to proteolysis [20, 21] . Together with other methods, such as gel-filtration, circular dichroism and fluorescence anisotropy, this assay supports a significant stabilization of the LBD in the presence of ligand and co-regulators. In addition, a comparison of crystallographic temperature factors [8] and NMR studies on LBD dynamics [22] demonstrated that the lower portion of the Fig. (3) . VDR ligand structures. The 3-dimensional structures of the agonistic and antagonistic VDR ligands discussed in the review are shown. The structures of the agonists were obtained from their crystallized complexes with human and rat VDR, whereas the structures of Gemini and the three antagonists were obtained from MD simulations with human VDR. At the example of 1α,25(OH)2D3 also the three pairs of anchoring VDR residues are indicated.
LBD (helices 4, 5, 6, 7, 11, 12 and parts of H3) is less rigid than the upper portion (helices 1, 2, 8, 9, 10 and the other half of H3) (Fig. 2) . Importantly, the lower portion, in particular H12 [23] , is rather dynamic in apo-structures, but shows significantly slower dynamics after ligand and coregulator binding. CoRs bind in the absence of ligand to the LBD and partially stabilize the apo-conformation [24] . Therefore, the relative amount of CoR and CoA proteins influences the equilibrium between the active and inactive NR LBD conformations [25] . This is of special importance for understanding the functional profile of the VDR ligand Gemini.
The members of the NR superfamily differ in the dynamic behavior of their LBDs. The LBDs of true endocrine members, such as VDR, RAR and ER, undergo more dynamic changes than adopted orphans, such as PPARs and PXR. The LBD dynamics seems to be inversely proportional to the level basal transcriptional activity of the respective NR. For example, we have recently proposed that PPARs have significant basal transcriptional activity and that this may be related to the lower dynamics of H12 movement in these receptors [17] . The dynamic behavior of the LBD can also explain how selective modulators can fine-tune the activity of the receptor, i.e., there is more than a simple onoff light switch, but many dimmer-type intermediate states.
This may also apply to living cells where many endogenous co-regulators are present and where NRs are part of large multi-subunit complexes binding to DNA in a complex chromatin environment. In addition, the relative "strength" of a ligand's ability to activate its NR may reflect its tightness of binding and probability of LBD occupancy. The cyclical fashion, in which NRs bind to their target promoters and recruit co-regulator proteins [26] , is another sign of the dynamic behavior of NRs.
1α,25(OH)2D3 SIGNALING
The VDR is one of the 11 true endocrine members of the NR superfamily and binds the biologically most active vitamin D metabolite, 1α,25(OH)2D3, with a Kd of approximately 0.1 nM. 1α,25(OH)2D3 is a key player in calcium homeostasis and bone mineralization [27] but also has antiproliferative and pro-differentional effects on various cell types [28] . In analogy to the above discussed mechanisms, the VDR LBD is the molecular switch of 1α,25(OH)2D3 signaling. An essential prerequisite for a direct modulation of transcription via 1α,25(OH)2D3-triggered LBD dynamics is the immediate location of the VDR to the basal transcriptional machinery of its target genes. This is mostly achieved through the specific binding of the VDR to a 1α,25(OH)2D3 response element (VDRE) in the regulatory regions of these genes ( Fig. 1) . Since the affinity of monomeric VDR to a typical hexameric core binding motif is not sufficient for the formation of a stable protein-DNA complex, the receptor binds as a heterodimer with RXR to VDREs, formed either by direct repeats of core binding motifs with 3 or 4 spacing nucleotides or by repeats with 7 to 9 intervening nucleotides [29, 30] .
CoR proteins link non-liganded, DNA-bound VDR, to enzymes with histone deacetylase activity that cause chromatin condensation [13] . This provides VDR with intrinsic repressive properties comparable to RARs and thyroid hormone receptors. The conformational change within VDR's LBD, after binding of 1α,25(OH)2D3, results in the replacement of the CoR by a CoA of the p160-family [12] , in complex with more general CoAs, such as CBP [31] . These CoA complexes have histone acetyltransferase activity, whose action on their major nuclear substrate, histone N-terminus tails, have the net effect of causing chromatin relaxation [32] . In a subsequent step, ligandactivated VDR changes rapidly from interacting with the CoAs of the p160-family to those of mediator complexes, such as TRAP220/DRIP205 [33] . The mediator complexes, which consist of approximately 15-20 proteins, build a bridge to the basal transcription machinery [34] . In this way ligand-activated VDR executes two tasks, the modification of chromatin and the regulation of transcription. These ligand-triggered protein-protein interactions are the central molecular events of nuclear 1α,25(OH)2D3 signaling.
THE VDR-LBD CRYSTAL STRUCTURE
The crystal structure of the VDR LBD [35] is closely related to the LBD of the endocrine NR RAR [11] (Fig. 2) . The most noticeable difference between both LBDs concerns the connection between helices 1 and 3, which is shifted outward in VDR, and the loop between helices 6 and 7, which is also shifted to the surface. Both differences lead to a larger ligand-binding pocket for 1α,25(OH)2D3 compared to that for all-trans retinoic acid. The ligand-binding pocket of the VDR is significantly larger (697 Å 3 ) than that of ER (369 Å 3 ), progesterone receptor (422 Å 3 ) or RAR (421 Å 3 ). This larger pocket volume is not required because 1α,25(OH)2D3 is a smaller molecule. Subsequently the ligand occupies only 56 % of the volume compared to the 63, 67 and 66 % calculated with estradiol, progesterone and all-trans retinoic acid, respectively.
Despite the absence of a CoA RID, H12 of the human VDR LBD was found to be in the agonist position and makes two direct van der Waals contacts via V418 and F422 with the methyl-group of the ligand [35] . The position of H12 is further stabilized by several hydrophobic contacts involving its residues T415, L417, V418, L419, V421 and F422 in connection with the H3 residues N232, V234, S235, I238 and Q239, the H5 residues A267 and I268 and the H11 residues H397 and Y401. In addition, H12 is stabilized by two polar interactions involving the conserved salt bridge K246 (H3)-E420 (H12) and a hydrogen bond between S235 (H3) and T415 (H12). Since some of these residues (V234, I268, H397 and T401) also interact with 1α,25(OH)2D3, the ligand has direct control of H12 positioning.
In the VDR LBD crystal structure [35] the A-ring of 1α,25(OH)2D3 adopts a β-chair conformation [36] with the 1-OH-and 3-OH-groups in equatorial and axial orientations, respectively (Fig. 3) . The inner surface of the VDR ligandbinding pocket is formed predominantly by hydrophobic residues. The three anchoring points of the ligand are hydrogen bonds between the 1-OH-group and S237 (H3)/R274 (H5), the 3-OH-group and S278 (H5)/Y143 (H1) and the 25-OH-group and H305 (loop between helices 6 and 7)/H397 (H11). The conjugated triene connecting the A-and C-ring is tightly fitted in a hydrophobic channel sandwiched between S275 (loop between H 5 and a β-sheet) and W286 (β-sheet) on one side and L233 (H 3) on the other side, while exclusively hydrophobic residues surround the CD-ring.
MOLECULAR EVALUATION OF 1α,25(OH)2D3 ANA-LOGUES
More than 3000 synthetic analogues of 1α,25(OH)2D3 are presently known and the majority of them carry a modification in their aliphatic side chain [37] . 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis [36] . Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists [38, 39] . All these compounds bind to the VDR LBD, which can be stabilized either in an agonistic or an antagonistic/inverse agonistic conformation.
The most detailed information about the molecular mechanisms of the analogues can be obtained from crystal structures. In addition to the above discussed complex with the natural hormone [35] , the VDR LBD has been crystallized with a few synthetic agonists (for details see the next two sections), but neither with antagonists nor with Gemini (although there is preliminary information on the zebrafish VDR LBD-Gemini structure [40] ) (Fig. 3) . However, docking of a ligand into the VDR ligand-binding pocket is probably a much more dynamic process than the "static" crystallography can monitor. Therefore, Gemini, antagonists and selected agonists were analyzed by molecular dynamics (MD) simulations. Moreover, a number of biochemical methods were used to analyze the mechanisms of action of 1α,25(OH)2D3 analogues. Traditional ligand binding assays are routinely performed to get an idea of the receptor-ligand interaction affinity, but they do not visualize the action of the molecular switch and its associated conformational changes. The latter can be visualized by in vitro methods, such as limited protease digestion, ligand-dependent gelshift and supershift assays [41] .
The limited protease digestion assay monitors, in which conformation the VDR was at the moment of a protease "snapshot". It is traditionally performed in a DNAindependent fashion, but more accurate results are obtained in presence of RXR, DNA and co-regulators [42] . The profile of more than 100 different VDR ligands has been compared in this assay system. Most of these ligands predominantly stabilize a large fragment of the VDR LBD (c1LPD, from R173 to the C-terminus at position 427) [43] indicating the agonistic receptor conformation. In the pre-sence of RXR and a VDRE, 1α,25(OH)2D3 and superagonists stabilize the agonistic VDR conformation with an EC50-value of approximately 0.1 nM [44] . All presently tested superagonists demonstrate the same high sensitivity for stabilizing VDR within DNA-bound VDR-RXR heterodimers, but with VDR monomers in solution they show individual EC50-values in the order of 1 to 20 nM [43] . This suggests that VDR's LBD reaches its full ligand sensitivity only as a component of a DNA-bound VDR-RXR heterodimer. At present stage, comparable type of information cannot be obtained from crystal structures.
The ligand-dependent gelshift represents a DNA-dependent assay for the analysis of the functionality of VDR-RXR heterodimers, since it monitors receptor dimerization, DNA binding and ligand interaction at the same time [41, 45] . In this assay the complex formation of VDR-RXR heterodimers on a VDRE is measured as a function of ligand concentration. The EC50-value of 0.1 to 0.2 nM [46] [47] [48] for 1α,25(OH)2D3 was found to be independent of sequence variations between natural VDREs [30] . A comparison of some prominent superagonists, such as MC1288, KH1060 and EB1089, showed that all of them have an EC50-value of approximately 0.1 nM. This means that at the level of complex formation of VDR-RXR heterodimers on DNA in vitro, they are not much more potent than the natural hormone [30, 43, 48] .
The supershift assay is a gelshift assay in the presence of CoAs or CoRs and demonstrates the ligand-triggered interaction between DNA-bound VDR-RXR heterodimers and coregulators [48] . For the interaction of DNA-bound VDR-RXR heterodimers with CoAs this assay provided for the natural hormone as well as for all tested superagonists EC50-values in the order of 0.1 nM. Therefore, ligand-dependent gelshift and supershift assays provide the same quality of information. The concentration value of 0.1 nM seems to be a lower threshold for VDR activation, which even superagonists cannot pass in these assays. However, VDR ligands differ in their pharmacokinetic profile and metabolism rate, which cannot be deduced in a simple way from crystal structure or biochemical data [49] . These might explain the higher activity of superagonists in vivo.
20-EPI VDR AGONISTS
The 20-epi analogues MC1288 (20-epi-1α,25(OH)2D3) and KH1060 (1α,25(OH)2-(20S)-22-oxa-24,26,27-trihomovitamin D3) (Fig. 3) were the first synthetic VDR ligands that were co-crystallized with the receptor [50] . Interestingly, the VDR-MC1288 and VDR-KH1060 complexes show the very low root mean square deviations (RMSDs) on the positions of their C α atoms of only 0.08 Å and 0.14 Å, respectively, when compared with VDR-1α,25(OH)2D3 complex [50] . Variations concern only some side chains located at the surface of the protein. Contrary to the belief that the 20-epi analogues are inducing a different agonist conformation, the overall conformation and especially the position of H12 are strictly maintained in all three complexes. Furthermore, the RMSDs of all atoms comprising the ligand-binding pocket are 0.09 Å for the VDR-MC1288 complex and 0.12 Å for the VDR-KH1060 complex. Whereas the sizes of 1α,25(OH)2D3, MC1288 and KH1060 are 381 Å 3 , 375 Å 3 and 392 Å 3 , respectively, the volume of the ligand-binding pocket remains unaltered in the three complexes (697 Å 3 ), so that the ligands occupy only 55-56 % of its volume.
The A-, seco-B, CD-rings of MC1288 and KH1060 form identical contacts as described above for the VDR-1α,25 (OH)2D3 complex as well as the OH-groups use the same three anchoring points [50] . When comparing the natural ligand and MC1288, the main difference observed is the positioning of the methyl-group at carbon 21, which results in different contacts with V300, L309 and H397. Other notable changes in protein-ligand contacts between these two molecules involve the methyl-groups at positions 23 (H305), 24 (H397) and 27 (H397 and V418). The major differences observed between KH1060 and 1α,25(OH)2D3 are the tighter and more numerous ligand-protein contacts. The oxygen atom at carbon 22 forms a van der Waals contact with V300 and the methyl-groups C26a and C27a, which are specific to KH1060, form additional contacts with H3, the loop between helices H6 and H7, H11and H12.
In all three complexes, the ligand is rather tightly bound to the receptor around the A-, seco-B, C-, and D-rings. In contrast, the aliphatic side chain is less constrained, thus allowing alternative conformations of the 17β-chain for the natural and the 20-epi ligands. The distances between the 25-OH-, 1-OH-and 3-OH-groups are similar for the three complexes and must be maintained to obtain an active conformation. In the case of the VDR-MC1288 complex, the CD-rings are slightly tilted, revealing an additional degree of freedom to orient the 17β-chain. The remaining section of the pocket is large enough to accommodate different variants of the long aliphatic chain of 1α,25(OH)2D3 analogues. The chain flexibility allows the different ligands to adapt to the pocket and to contact the anchoring histidine pair by their 25-OH-group.
Taken together, the interaction between the 20-epi agonists and the VDR does not result in significant variations from the LBD conformation induced by the natural ligand. However, the 20-epi analogues make new contacts with the protein as a consequence of the different path adopted by their side chain. Additional interactions of KH1060 due to the 20-epimerization and the extra methyl-groups could explain the higher stability and longer half-life of its complex with VDR. The VDR-MC1288 complex is energetically more favorable than the more tense conformation of the natural ligand. Limited protease digestion assays show that VDR-20-epi analogue complexes are more resistant to digestion over time [47, 51] suggesting that the half-life of the active conformation is the main factor responsible for the formation of a more potent complex with CoA and subsequent higher transcriptional activity.
OTHER VDR SUPERAGONISTS
The human VDR LBD has also been crystallized in complex with the analogues MC903 (calcipotriol) [52] , EB1089 (seocalcitol) [52] and TX522 (14-epi conformation) [53] (Fig. 3) . In addition, the rat VDR LBD was crystallized with 1α,25(OH)2D3 and the 2-substituted analogues 2-methylene-19-nor-(20S)-1α,25(OH)2D3 (2MD), 1α-hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol (2MbisP) and 2α-methyl-19-nor-1α,25(OH)2D3 (2AM20R) [54] (Fig.  3) . In all crystal structures a single conformation with a RMSDs of their C α -atom positions between 0.09 and 0.37 Å in comparison to the VDR-1α,25(OH)2D3 complex were observed. The LBDs of human and rat VDR show high similarity with a RMSD of their backbone C α -atoms of only 0.53 Å [54] . Moreover, also with these analogues the position and conformation of H12 was strictly maintained.
The rat VDR LBD was co-crystallized with a CoA RID peptide, which binds in a surface groove formed by helices 3, 4 and 12 [54] . This interaction buries approximately 507 Å 2 of the receptor's surface area. The electrostatic and hydrophobic interactions with the RID peptide provide additional significant stabilization of the active conformation of the rat VDR and despite the rather different ligands this CoA interaction remained constant. Interestingly, in the case of human VDR, the active conformation is stabilized by the interaction with H3n [35] indicating the high plasticity of the LBD in taking the energetically most favorable conformation.
The varying side chain length of the ligands resulted only in small differences and degrees of freedom in the distances between the OH-groups at the anchoring points S237/R274, Y143/S278 and H305/H397. Despite an increased rigidity and length of the side chain of EB1089 its 25-OH-group is shifted by only 0.4 Å. The triple bond of the side chain of TX522 causes a shift of carbon 21 by 0.4 Å and because of its rigidity the side chain takes another pathway in the pocket and makes an additional contact with I268 (H 5) [53] . Due to the 14-epi-configuration, the CD rings of TX522 are shifted by 0.5 Å and carbon 12 makes closer contacts with V300 (H6) [53] . These closer and additional contacts between the analogue and the ligand-binding pocket may cause TX522 to dissociate slower from the VDR than the natural hormone although this is in contrast to an analysis by limited protease digestion [55] . A remarkable feature of MC903 is the absence of a direct contact with H12, while its cyclopropyl-group interacts with the C α -atom of A231 (H3) [52] .
The binding of 2MD, 2MbisP and 2AM20R to the rat VDR provides another example that the positions of the amino acids in the ligand-binding pocket do not change in comparison to the complex with the natural hormone [54] . The cavity is quite large and the VDR accepts the structural modifications at carbon 2 without any conformational disruption. The CD-ring of 2MD is tilted and the 17β-aliphatic side chain is permitted substantial flexibility within the pocket, while the 25-OH-group still occupies the same position as that of the natural ligand. The conformation of the entire core portion of 2MbisP closely resembles that of 1α,25(OH)2D3, but due to the absence of the 25-OH-group in the truncated side chain a water molecule has to provide the link to the two anchoring histidine residues. However, the lack of a direct contact with the anchoring points increases the mobility of 2MbisP and decreases the half-life of the complex proportionally. The A-ring of the analogue 2AM20R takes the β-chair conformation and the 1-OH-group is positioned equatorial. However, the expected differences in the biological activity of the carbon 2-modified analogues are not reflected by the crystal structure data.
NON-STEROIDAL VDR AGONISTS
Most 1α,25(OH)2D3 analogues carry only rather minor modifications compared to the natural hormone and stabilize the same agonistic VDR conformation [50] . However, there are also semi-steroidal analogues, which either have significant changes in their A-, C-or D-rings, such as CD ring deletion [56] , or carry substantial additions, such as the second side chain in Gemini [48, 57] . Non-steroidal ligands are known for several members of the NR superfamily, such as flutamine for the androgen receptor [58] and raloxifene for the ER [59] . For the VDR initially only diphenylmethane derivatives, such as LG190178 [60, 61] and its derivatives [62, 63] , have been described as pure non-steroidal agonistic ligands. Recently, a novel class of non-steroidal compounds, the bis-aromatic molecule CD4528 and its derivatives, was described [64] . A comparison of LG190178 and CD4528 showed that both type of compounds induce VDR-RXR heterodimer complex formation on a VDRE, stabilize the agonistic conformation of the VDR LBD, enable the interaction of VDR with CoA proteins and contact with their OH-groups the same three anchoring points within the ligand-binding pocket as 1α,25(OH)2D3 [64] .
MD simulations demonstrated that both types of nonsteroidal VDR ligands take a shape within the ligandbinding pocket that is very similar to that of the natural ligand. The fact that the non-steroidal ligands have a significant effect on the activity of the VDR, indicates that the seco-steroid backbone of 1α,25(OH)2D3 is of less importance than the positioning of the three anchoring OHgroups. The more exactly the non-steroidal compounds place their OH-groups, the lower seem to be their respective EC50-values in the different in vitro assays. CD4528 is mimicking the natural hormone best and was found to be in vitro at least 5-times more potent than LG190178. In living cells CD4528 was only 2-times less potent than 1α,25(OH)2D3 and induced mRNA expression of the VDR target gene CYP24 in a comparable fashion [64] . Taken together, at an appropriate non-calcemic dose (150 µg/kg in mice) [64] CD4528 acts very much like 1α,25(OH)2D3 both in vitro and in vivo.
VDR ANTAGONISTS
Agonism and antagonism of NR ligands are closely related processes. Both type of ligands bind to the same site of the ligand-binding pocket, but agonists stabilize the position of H12 in the agonistic conformation, while antagonists prevent this stabilization. Two types of VDR antagonists are known [65] . These are the 25-carboxylic esters exemplified by ZK159222 [66] and ZK168281 [46] and the 26,23-lactone TEI-9647 [67] [68] [69] (Fig. 3) . Compared to the natural hormone, both types of compounds have relatively bulky ring structures in their side chains. In addition, ZK159222 and ZK168281 carry much longer side chains than TEI-9647. ZK159222 and TEI-9647 were characterized as partial antagonists, whereas ZK168281 was found to be a pure antagonist [65.70] . ZK159222 and ZK168281 have an affinity to the VDR that is comparable to that of 1α,25(OH)2D3, while that of TEI-9647 is at least 10-fold lower [65] .
In limited protease digestion assays only antagonists stabilize a VDR fragment, c2LPD (from R173 to R402), that specifically represents the antagonistic conformation [46, 66] . Interestingly, the antagonist-specific VDR fragment that is stabilized by TEI-9647 shows a slight migration difference compared to that is stabilized by ZK159222 [55, 71] suggesting a difference between both antagonistic conformations. In the antagonistic conformation of its LBD the interaction of VDR with CoAs is significantly reduced or even abolished [65] . MD simulations of the VDR-LBD complexed with ZK159222 and ZK168281 suggest that the difference between partial and true antagonism arises from a more drastic displacement of H12 by ZK168281 than by ZK159222 [70] .
Selective antagonism as exhibited by TEI-9647, ZK-159222 or the synthetic ER ligands tamoxifen and raloxifene appears to be a complex phenomenon that arises through the interplay of a number of factors, such as differential ligand effects on the transactivation of the NR, the type of coregulator recruited as well as the cell and promoter context. For example, the antagonistic function of ZK159222 has been shown to depend on the cell-specific ratio between VDR and RXR proteins [72] . The most critical parameter for judging the quality of an antagonist appears to be the amount of its residual agonism, which showed to have for TEI-9647 a rather high level [65, 71] . Interestingly, in rat cells the residual agonistic activity of TEI-9647 is significantly higher than in human cells, because the rodent-specific VDR amino acids S403 and N410 display more and stronger interactions than C403 and C410 in human VDR [73] .
The lactone ring of TEI-9647 is more bulky than the end of the side chain of the natural hormone and cannot interact effectively with the anchoring point H305/H397 [73] . Moreover, the carbonyl-group of the lactone ring cannot interact directly with F422 (H12), so that finally some steric hindrance is created. This destabilizes the position of H12, induces flexibility to the H12 and makes a stable interaction of the VDR LBD with CoA proteins unlikely. However, TEI-9647 lacks an extended side chain and disturbs H12 less than ZK168281, so that only the 26,23-lactone but not the 25-carboxylic ester is affected by the increased interaction potential of S403 and N410 in rodent VDR [73] . This results in a loss of the antagonist function of TEI-9647 in rodents. Double mutagenesis C403S/C410N of the human VDR resulted in the same lack of antagonism as observed in rat cells. The increasing agonistic action of TEI-9647 parallels to the gain of interaction of the VDR with CoA protein and the lack of stabilization of the antagonistic conformation of the receptor. MD simulations indicated that TEI-9647 reduces the stability of H12 of the human VDR LBD. In contrast, N410 of the rat VDR stabilizes via backbone contacts the interaction between helices 11 and 12 resulting in TEI-9647 becoming a weak agonist in this species. Chemical modifications of TEI-9647, in particular at carbon 2, significantly increase the VDR binding affinity [74, 75] . These compounds cannot sit as deep at the bottom of the ligand-binding pocket as an unsubstituted ligand. This decreases the distance between the carbonyl-group of the lactone ring and F422 and provides the respective compounds with a higher antagonistic potential than the parental compound.
IS THERE A DIFFERENCE BETWEEN ANTAGO-NISTS AND INVERSE AGONISTS?
Common in the molecular mechanism of antagonists and inverse agonists is their ability to promote the interaction of their receptor with CoR proteins and to inhibit contact with CoA proteins. Classical endocrine NRs, such as VDR, show very low basal activity in the absence of ligand, while adopted orphan NRs, such as constitutive orphan receptor (CAR) and PPAR [17, 76] , display significant amount of constitutive activity. Therefore, antagonists act after a preceding activation of their target receptor by an agonist, while inverse agonists antagonize the ligand-independent high basal activity of their receptor. The true VDR antagonist ZK168281 and the human CAR inverse agonist clotrimazole are both effective inhibitors of CoA interaction of their respective receptors [77] . Moreover, concerning potent CoR recruitment ZK168281 also resembles the mouse CAR inverse agonist androstanol [77] .
MD simulations resulted in comparable models for the LBDs of VDR and both CARs complexed with a CoR-RID peptide and ZK168281, clotrimazole and androstanol, respectively [77] . A salt bridge between the CoR and a conserved lysine in H4 of the NR-LBDs are important for the stability of the antagonist-/inverse agonist-stabilized LBD-CoR complex. Moreover, the models indicate a stabilization of H12 by direct contacts with residues of the CoR. However, the extended side chain of ZK168281 both pushes H12 from its agonistic position [70] and directly contacts and stabilizes the CoR-RID [77] . In contrast, clotrimazole and androstanol do not contact the H397 homologues Y326 and Y336 in human and mouse CAR and also do not interact with the CoR-RID. These properties make ZK-168281 a more effective regulator of the co-regulator exchange than clotrimazole and androstanol. A stabilized position of H12 by CoR contacts [77] represents energetically a more favorable state than that of a free-floating H12 as suggested in the "mouse-trap" model [16] . It has to be noted that in contrast to the CoA interaction, which is dependent of a fixed position of H12, the H is not needed for CoR interaction. In fact, H12 has to move from its position in the agonistic LBD conformation to a perpendi-cular position, where it does not disturb the contact between LBD and CoR. There-fore, fixation of H12 in the antagonistic/inverse agonistic conformation seems to be only energetically favorable but of no specific function. In summary, the observation that ZK168281, clotrimazole and androstanol have comparable effects on the co-regulator interaction of their respective receptors [77] , suggests that antagonists and inverse agonists may be taken into the same ligand class that can be clearly distinguished from the class of agonists.
GEMINI
Gemini is a 1α,25(OH)2D3 analogue with two identical side chains. Although of significantly increased volume (25 %) it binds to the VDR [48] (Fig. 3) . In the presence of CoAs, RXR and DNA, Gemini stabilizes the VDR in its agonistic conformation [48, 78] . MD simulations of the Gemini-VDR complex demonstrated that one of the two side chains of Gemini takes the same location as in the natural hormone, whereas for the second side chain two approximately equal positions were identified [79] (Fig. 4) . As agonist, Gemini prefers possibility 1, but as inverse agonist it takes possibility 2. In the absence of RXR, VDRE and CoA, Gemini takes the latter conformation [38] , which, in the limited protease digestion assay, is visible as conformation c3LPD (from R173 to R391) [78] . Equally, supramolar CoR concentrations shift Gemini from an agonist to an inverse agonist, which actively recruits CoR to the VDR and thus mediates repression of 1α,25(OH)2D3 target genes [39] . MD simulations indicated that the second side chain of Gemini creates tension within the LBD of VDR, Fig. (4) . conformations. Based on MD simulations the two side chain compound Gemini can bind to the ligand-binding pocket of VDR in two different conformations. In conformation 1 (blue) Gemini acts as an agonist, while in conformation 2 (pink) it behaves as an inverse agonist. The 1α,25(OH)2D3 molecule (green) is shown as a reference.
which, in excess of CoR proteins, can be released by shifting H12 into an inverse agonistic/antagonistic position. A classical antagonist such as ZK168281, however, can never convert to a superagonist because its bulky side chains cause steric hindrance to H12, but as a conditional inverse agonist, Gemini turns into an agonist, or even a superago-nist, when VDR binds as a heterodimer with RXR to DNA and is exposed to high CoA levels [48] . This suggests that Gemini may function as a sensor for cell-specific CoA/CoR ratios.
CONCLUSION
The ligand-triggered dynamic exchange of CoA and CoR proteins binding to the VDR is the molecular basis of the action of agonists and antagonists/inverse agonists. The VDR LBD is the molecular switch in 1α,25(OH)2D3 signaling and its agonistic and antagonistic/inverse agonistic conformation explains well the functional profile of the different types of ligands. The most critical issue in this aspect is the positioning of H12 and the resulting interaction with either CoR or CoA proteins. Therefore, analyzing the stabilization of VDR conformations by 1α,25(OH)2D3 analogues is a quick and informative way for their in vitro evaluation. MD simulations and crystal structures, however, clearly provide more detailed information, although even the latter methods were not able to explain the superagonistic profile of the most popular VDR ligands. In contrast, the molecular mechanisms and differences between VDR antagonists are in the meanwhile well understood. At the present Gemini remains a most interesting VDR ligand, since it can switch from an inverse agonist to a superagonist and may function as a sensor for the cell-specific CoA/CoR ratio. Finally, the evaluation of the profile of a VDR ligand 
